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Abstract
Lung cancer chemoprevention, especially in high-risk former smokers, has great potential to 
reduce lung cancer incidence and mortality. Thiazolidinediones prevent lung cancer in preclinical 
studies, and diabetics receiving thiazolidinediones have lower lung cancer rates which led to our 
double-blind, randomized, phase II placebo-controlled trial of oral pioglitazone in high risk 
current or former smokers with sputum cytologic atypia or known endobronchial dysplasia. 
Bronchoscopy was performed at study entry and after completing of six months of treatment. 
Biopsies were histologically scored, and primary endpoint analysis tested worst biopsy scores 
(Max) between groups; Dysplasia index (DI) and average score (Avg) changes were secondary 
endpoints. Biopsies also received an inflammation score. The trial accrued 92 subjects (47 
Corresponding Author: Robert L. Keith, Division of Pulmonary Sciences and Critical Care Medicine, Eastern Colorado VA Healthcare 
System, Rocky Mountain Regional VA Medical Center, A3-350, 1700 N. Wheeling St., Aurora, CO 80045, 
Robert.keith@ucdenver.edu, Phone: 720-857-5120. 
Conflict of Interest Disclosure Statement: The authors certify that they have NO affiliations with or involvement in any organization or 
entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, 
consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial 
interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed 
in this manuscript.
HHS Public Access
Author manuscript
Cancer Prev Res (Phila). Author manuscript; available in PMC 2020 April 01.
Published in final edited form as:
Cancer Prev Res (Phila). 2019 October ; 12(10): 721–730. doi:10.1158/1940-6207.CAPR-19-0006.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
pioglitazone, 45 placebo), and 76 completed both bronchoscopies (39 pioglitazone, 37 placebo). 
Baseline dysplasia was significantly worse for current smokers, and 64% of subjects had mild or 
greater dysplasia at study entry. Subjects receiving pioglitazone did not exhibit improvement in 
bronchial dysplasia. Former smokers treated with pioglitazone exhibited a slight improvement in 
Max, while current smokers exhibited slight worsening. While statistically significant changes in 
Avg and DI were not observed in the treatment group, former smokers exhibited a slight decrease 
in both Avg and DI. Negligible Avg and DI changes occurred in current smokers. A trend towards 
decreased Ki-67 labeling index occurred in former smokers with baseline dysplasia receiving 
pioglitazone. While pioglitazone did not improve endobronchial histology in this high-risk cohort, 
specific lesions showed histologic improvement and further study is needed to better characterize 
responsive dysplasia.
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Introduction:
Lung cancer is the leading cause of cancer death in the United States and worldwide(1). The 
majority of US diagnoses occur in former smokers, and effective chemopreventive strategies 
(beyond smoking cessation) could lead to dramatic improvements in survival(2). 
Chemoprevention involves the use of agents to reverse or inhibit the carcinogenic process 
and has been successfully applied to common malignancies other than lung. 
Chemoprevention may take on additional significance with the implementation of lung 
cancer screening. Low dose CT scans in high risk populations have been shown to decrease 
lung cancer death rates(3), and widespread adoption could result in a stage shift and more 
long term survivors. This group would remain at high risk for a second primary lung cancer 
and would be ideal for chemopreventive interventions beyond smoking cessation(4). The 
World Health Organization classification for lung cancer recognizes distinct endobronchial 
lesions which are precursors of invasive lung cancer(5). For example, the development of 
squamous cell lung cancer starts with normal epithelium and progresses through 
hyperplasia, metaplasia, dysplasia (mild, moderate, and severe), and carcinoma in situ. To 
date no intermediate biomarkers have been validated for the interception of lung cancer, in 
part due to the lack of proven therapy, and histology is currently considered the best 
marker(6). Our group has shown that the persistence of endobronchial dysplasia on repeat 
biopsies is associated with an increased risk of developing invasive squamous cell lung 
cancer(7). By identifying and focusing therapeutic interventions on pre-malignant stages of 
the disease, reductions in incidence and mortality may become a realizable goal(6).
Products of the arachidonic acid pathway, particularly the prostaglandins (PGs), play a 
critical role in lung carcinogenesis and chemoprevention. Large epidemiologic studies have 
shown an association between regular aspirin use and decreased rates of certain cancers. Our 
group has demonstrated chemoprevention of lung cancer by increasing prostacyclin 
(prostaglandin I2, PGI2) levels in multiple pre-clinical models(8,9). These findings led to a 
clinical trial showing oral iloprost (a prostacyclin analogue) significantly improved 
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endobronchial dysplasia in former smokers(10). Additional studies focusing on the 
chemopreventive mechanism have shown prostacyclin’s effects to be independent of the 
single cell-surface PGI2 receptor (IP) and may rely on PGI2’s ability to act as a peroxisome 
proliferator activated receptor gamma (PPARγ) agonist(11). The thiazolidinediones (TZDs) 
are PPARγ agonists commonly used in the treatment of diabetes and the TZD pioglitazone 
has been studied in multiple pre-clinical cancer models. Pre-clinical studies of genetically 
modified PPARγ overexpressors and oral PPARγ agonists have confirmed that PPARγ 
activation promotes differentiation(12,13), inhibits tumor growth, and prevents progression 
of pre-invasive lesions in murine models(14). Oral, and more recently inhaled, pioglitazone 
has been shown in pre-clinical models to prevent both adeno and squamous cell carcinoma 
as a single agent or in combination with inhaled steroids and metformin(15). Rationale for a 
role in lung cancer chemoprevention was further supported by a large study focusing on 
lung, prostate, and colon cancer rates in diabetic Veterans treated with TZDs. Govindarajan 
and colleagues reported a 33% decrease in lung cancer incidence compared to non-TZD 
users, suggesting the PPARγ activation may chemoprevent lung cancer. This same group 
also showed a reduction in head and neck squamous cell cancer by 41–55% with TZD 
use(16). Additionally, pioglitazone has been studied in oral leukoplakia (a tobacco related 
pre-malignant lesion, ) (17). In this trial twenty-one subjects were treated with once daily 
pioglitazone for 12 weeks and a partial response was seen in 15 subjects (2 had stable 
disease and 4 progressed). The combination of pre-clinical and epidemiologic data strongly 
supported a phase II trial of oral pioglitazone.
Prior randomized phase III lung cancer chemoprevention trials based on epidemiologic 
studies all proved negative. However, several Phase II studies revealed differences between 
current and former smokers regarding amount and extent of central airway damage(18–20). 
Subjects with tobacco smoke exposure, chronic obstructive lung disease, and sputum 
cytologic atypia have rates of lung cancer greater than 1% yearly and are a high-risk 
population for prevention studies(21). Based on extensive pre-clinical data and 
epidemiologic observations we instituted a single-center, double-blind, placebo-controlled 
phase II trial of pioglitazone in current and former smokers with sputum cytologic or 
endobronchial atypia using improvement in bronchial dysplasia (Max) as the primary 
endpoint.
Materials and Methods:
Study Design:
The pioglitazone lung cancer chemoprevention study was a phase II, randomized, double-
blind, placebo-controlled trial of oral pioglitazone in subjects at increased risk for lung 
cancer (defined as current or former smokers with ≥ 10 pack year smoking history, at least 
mild sputum cytologic atypia, airflow limitation [FEV1 % predicted < 0.70], or a history of 
biopsy proven endobronchial dysplasia). The majority of subjects were recruited from 
pulmonary medicine clinics. Exclusion criteria included: type I or II diabetes mellitus; 
severe COPD (GOLD Stage III or IV); prior history of cancer within the past 5 years; 
history of coronary artery disease or congestive heart failure (LVEF<50%); significant 
comorbid disease or inability to undergo two bronchoscopies; hypoxemia requiring the use 
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of supplemental oxygen; and carcinoma in situ or invasive cancer on endobronchial biopsy. 
Sputum was collected and cytology was graded by a single cytopathologist (DTM) using 
previously published methods(21). Autofluorescence and/or white light bronchoscopy was 
performed before randomization and after 6 months of treatment, with 6 standard 
endobronchial sites biopsied (all were carini, identified as RUL, RML, RB6, LUL, LUDB, 
and LB6), along with all other visually suspicious appearing areas. In addition to 
bronchoscopy, study subjects had full pulmonary function testing at study entry and 
conclusion, trans-thoracic echocardiogram prior to study entry to evaluate cardiac function, 
and high-resolution chest CT at study entry and after 6 months of treatment. The study was 
conducted according to the Belmont Report ethical guidelines and was approved by the 
Colorado Multi-Institutional Review Board.
The trial enrolled 92 subjects, and after obtaining written informed consent, participants 
were randomized to treatment groups using a stratified block randomization with smoking 
status (current vs. former) as the stratification factor and block sizes of 4. The randomization 
sequence was generated by the trial biostatistician prior to trial initiation and stored in a 
password-protected spreadsheet accessible only to the trial biostatistician and study 
administrator. Subjects were randomized only after confirmation of eligibility and 
completion of pre-study testing (spirometry, echocardiogram, chest CT, and blood chemistry 
analyses). Blinding of treatment group for each subject was maintained throughout the trial. 
Following randomization, subjects were started on either pioglitazone (30 mg) or placebo at 
dose of 1 tablet QD. Subjects had a monthly clinical evaluation, including EKG and blood 
chemistry analysis. Following six months of treatment subjects had full pulmonary function 
testing, a high-resolution chest CT scan, and a second bronchoscopy was performed with 
repeat biopsies at each of the baseline sites in addition to any new sites suspicious for 
dysplasia. Adverse events were monitored and reported twice yearly to an independent data 
safety and monitoring board (DSMB). A final clinical visit occurred one month after 
completing the trial and subjects are currently undergoing passive follow-up through the 
Colorado Cancer Registry (i.e. annual phone call). All current smokers were counseled and 
offered assistance with smoking cessation. This trial was listed and registered on 
ClinicalTrials.gov (Identifier: ). Pioglitazone was purchased by the Denver VA research 
pharmacy and they produced the identical appearing study medication and placebo tablets.
Biopsy Analysis:
All endobronchial biopsies were formalin fixed, paraffin embedded and stained with 
hematoxylin and eosin (H&E) for subsequent morphologic evaluation and classification. 
Biopsies were classified into one of eight WHO defined categories(5) and assigned a score 
according to the following scale: 1 = normal bronchial epithelium; 2 = reserve cell 
hyperplasia; 3 = squamous metaplasia without atypia; 4 = mild dysplasia; 5 = moderate 
dysplasia; 6 = severe dysplasia; 7 = carcinoma in situ (CIS); and 8 = invasive carcinoma. All 
biopsies were graded by the study pathologist (DTM) in a blinded fashion as to treatment 
group and were read after the completion of each bronchoscopy. Biopsies were also assigned 
a visual inflammation score. The inflammation scores were generated from microscopic 
review of H&E stained biopsy slides to characterize percent of cellularity attributed to 
Keith et al. Page 4
Cancer Prev Res (Phila). Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
inflammatory cells (0 = no significant inflammation, <5%; 1 = mild, 5–25%; 2 = moderate, 
25–75%; 3 = severe, >75%).
In addition to WHO histology scoring, epithelial proliferation, measured by Ki-67 
immunostaining, was conducted on biopsies from a subset of study participants performed 
by techniques previously described and implemented in our laboratory(20). In brief, the 
most dysplastic region of a biopsy was selected, at least 400 cells were graded for Ki-67 
positivity, where possible, throughout the entire epithelium and the percentage of positive 
cells recorded as the Ki-67 proliferative index. The primary antibody used for Ki-67 was 
Dako clone mib-1 BM28 mouse monoclonal (#B58720) at a dilution of 1:100.
Statistical Design and Analysis:
Endobronchial histology was summarized within each bronchoscopy. The primary endpoint 
was the change in worst (i.e. maximum, Max) histology score after 6 months of treatment. 
Secondary endpoints included the change in average of all biopsy scores (Avg) and in 
dysplasia index (DI - defined as the percentage of biopsies with mild dysplasia (a score of 4) 
or worse). The pre-specified primary analysis used change in Max histology after 6 months 
calculated using biopsies non-normal at baseline (i.e. those with a baseline histology score > 
1). All endpoints were analyzed within four different biopsy site groupings: all biopsies 
scored (n = 1,169), all biopsies from the six standard endobronchial sites only (n = 1,003), 
site-matched biopsy pairs from both bronchoscopies (n = 1,030), and site-matched biopsy 
pairs where the baseline biopsy was non-normal (n = 498).
Of the 92 enrolled subjects, 47 were randomized to pioglitazone and 45 to placebo. There 
were 44 current smokers enrolled (22 in each treatment arm) and 48 former smokers 
enrolled (25 in the pioglitazone arm and 23 in the placebo arm). The trial was monitored by 
an independent DSMB, and no interim analyses of treatment effects on histology were 
planned or conducted.
All analyses were pre-specified in a written statistical analysis plan (SAP) that followed 
from the trial protocol. The primary endpoint (and statistical analysis) measured the 
treatment effect of pioglitazone within former smokers by fitting a regression model Y = α0 
+ α1GROUP + α2BASELINE. Y represents the 6-month value of the dependent variable 
(Max histology score), GROUP represents a classification variable for the treatment group 
(1=pioglitazone, 2=placebo), BASELINE represents the value of the outcome measure at 
baseline, and α0, α1 and α2 represent the parameter estimates from the general linear model. 
The test of the difference between groups was the formal test of significance of the α1 
parameter. The primary analysis used the biopsy pairs which were non-normal at baseline. 
This regression analysis was performed using every combination of histology summary 
measure (Max, Avg, and DI), every set of biopsy grouping (all, reference sites, matched 
pairs, and baseline non-normal matched pairs), among all subjects, former smokers and 
current smokers. In total, 36 regression analyses were performed; all but the primary 
analysis were considered secondary analyses. Analyses using all subjects (i.e. former and 
current smokers) included smoking status as a covariate in the regression model. Results 
from all models are reported as point estimates of the treatment effect, 95% confidence 
intervals, and 2-sided p-values without adjustment for multiple comparisons.
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Results
Study Population:
A total of 6126 subjects were screened in the Denver VAMC pulmonary clinics from 2010 
until 2015. Two hundred fifty-nine subjects agreed to provide a screening sputum sample 
and ultimately 92 subjects were enrolled (Figure 1). The main reasons for not entering the 
trial included: lack of sputum cytologic atypia; reluctance to undergo multiple 
bronchoscopies; and travel issues. The study population consisted of 44 current smokers and 
48 former smokers, with 47 subjects randomized to pioglitazone and 45 to placebo. The only 
significant difference in baseline demographic or clinical characteristics between the two 
study groups was age at enrollment. The placebo group was older than those receiving 
pioglitazone (62.6 +/− 8.2 vs. 58.6 +/− 9.6 years of age, p=0.036). The groups were well 
matched for gender, ethnicity, tobacco exposure, time since smoking cessation, sputum 
cytology, and endobronchial histology (Table 1). Eighty four percent of the study subjects 
were male due to all recruitment occurring at the Denver VA Medical Center. Baseline 
bronchoscopy was completed in all 92 subjects, and follow-up bronchoscopies were 
completed in 76 subjects. Similar dropout rates were observed between the treatment groups 
(17% pioglitazone vs 18% placebo, p=0.92), with the main reason given as ‘refusing further 
treatment’ (i.e. not desiring a repeat bronchoscopy). The complete list of reasons for failing 
to complete the study is included in Figure 1. Five subjects successfully quit smoking during 
the trial, and two subjects resumed smoking. For analyses these subjects remained classified 
according to their stratification at randomization.
Histologic Analysis Baseline:
At baseline, there were no significant differences between the pioglitazone and placebo 
groups in any of the histology-based summary measures (Max, Avg, and DI). Using our 
entry criteria, 87% (80/92) of the subjects had at least one non-normal biopsy at baseline. 
Mild dysplasia or worse was observed in 25.1% (157/626) of our baseline biopsies and in 
65% (60/92) of subjects. At baseline (and consistent with prior studies(10)), current smokers 
had more endobronchial dysplasia than former smokers as evidenced by significantly higher 
Max (4.5 vs. 3.5, p=0.005), Avg score (2.6 vs. 1.8, p<0.001), and DI (34% vs. 16%, 
p=0.001).
Treatment:
Follow-up bronchoscopy was performed on 39 pioglitazone subjects (19 former smokers, 20 
current smokers) and 37 placebo subjects (19 former smokers, 18 current smokers). Overall 
results combining current and former smokers (depicted in Figure 2) showed no significant 
difference between treatment groups in the primary endpoint (change in Max histology in 
baseline non-normal pairs: 0.00; 95% CI (−0.79, 0.79); p = 1.00; Supplemental Table 1S). 
When analyzed according to smoking status, there was also no statistically significant 
difference between treatment groups (Figure 2 and data contained Table 1S). Former 
smokers treated with pioglitazone demonstrated a decrease (i.e. improvement) in Max 
histology when compared with former smokers treated with placebo (−0.40, 95% CI (−1.68, 
0.89), p=0.53, Table 1S) while current smokers treated with pioglitazone exhibited a mild 
increase (i.e. worsening) in histology when compared with current smokers treated with 
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placebo (0.32, 95% CI (−0.69, 1.34), p=0.52, Table 1S). In all 36 regression analyses of 
treatment effect (Table 1S), there were no statistically significant treatment effects observed. 
Within former smokers, all 12 analyses resulted in a slight improvement (i.e. decrease) in 
histology in subjects treated with pioglitazone as compared with placebo, with treatment 
effects ranging from −0.05 to −0.40. Within current smokers, the treatment effects ranged 
from −0.14 to 0.32, with 9 of the 12 analyses exhibiting a slight decrease in histology for 
pioglitazone-treated subjects.
Histologic Response:
Treatment effect was also analyzed using a dichotomous endpoint indicating whether or not 
a patient responded to treatment. A patient was defined as responding to treatment if the 
histology summary score (maximum or average) showed an improvement (i.e. decrease) by 
at least 1 unit. Separate response endpoints were defined using both Max and Avg. Logistic 
regression analysis was used to analyze whether response differed by treatment groups. The 
analysis of response was performed in all 24 combinations of endpoints (Max, Avg) and 
biopsy groupings within all subjects, former smokers, and current smokers. There was no 
statistically significant treatment effect observed in all analyses.
On a per subject analysis, 65% of subjects (47/72) who completed the trial had at least one 
site of dysplasia at baseline (23 pioglitazone, 24 placebo). Within this group, 40% (19/47) 
( of the subjects had their maximum histology regress (defined as improving by at least 1 
grade) (48% (1½3) pioglitazone, 33% (8/24) placebo, p=0.31); 43% (20/47) of the subjects 
had their maximum histology remain the same (30% (7/23) pioglitazone, 54% (13/24) 
placebo); and 17% (8/47) of the subjects had their maximum histology progress (defined as 
worsening by at least 1 grade) (22% (5/23) pioglitazone, 13% (3/24) placebo). In former 
smokers with dysplasia (score > 4) at baseline, there was a trend (−1.33, 95% CI −2.85–
0.19, p=0.082) towards pioglitazone improving histology.
Analyzing the data at a biopsy pair level, histologic improvement was seen in 27% 
(135/502) of the pairs, with improvement as great as 5 units observed. Histology was stable 
(i.e. did not change) in 48% (241/502) of the pairs, and progressed in 25% (126/502). There 
were 13 biopsy pairs for which change could not be determined due to an unsatisfactory 
endobronchial biopsy that could not be scored (7 at baseline and 6 at month 6). Within 
former smokers treated with pioglitazone, from the 130 scored biopsy pairs, 21% (27/130) 
exhibited improvement, 59% (77/130) exhibited stability and 20% (26/130) exhibited 
progression. When further limited to the 41 biopsy pairs which were non-normal at baseline 
(histologic diagnosis of > 2 on initial biopsy), 66% (27/41) of the pairs improved, 24% 
(10/41) were stable, and 10% (4/41) worsened. The rates in biopsy pairs with non-normal 
baseline histology observed among current smokers were 56% (44/78) improved, 23% 
(18/78) remained stable, and 21% (16/78) worsened. There was no significant difference in 
the distribution of response to treatment with pioglitazone between former and current 
smokers (p=0.32).
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Inflammation analysis (Figure 3):
All endobronchial biopsies received an inflammation score by the study pathologist, with the 
scores ranging from 0–3 (corresponding to no inflammation [0], mild [1], moderate [2], and 
severe [3]). When compared at baseline for the presence or absence of inflammation, former 
smokers exhibited significantly more inflammation than current smokers (39/48 [81%] vs 
26/44 [59%], p=0.02). There were no differences in baseline inflammation between the 
treatment and placebo groups (Table 1 and Figure 3). A stratified analysis of the primary 
endpoint (change in Max histology) based on the presence of inflammation at baseline 
showed treatment effects in the same direction in biopsies without inflammation with −0.25 
in former smokers (95% CI −2.27–1.78, p=0.72) and −0.43 in current smokers (95% CI 
−2.00–1.14, p=0.56). In biopsies with inflammation, results were in opposite directions with 
treatment effects of −0.54 in former smokers (95% CI −1.77–0.70, p=0.38) and 0.84 in 
current smokers (95% CI −0.55–2.24, p=0.22). For those treated with pioglitazone, 44% of 
subjects with mild inflammation at baseline improved, improvement rates for those with no 
inflammation (25%) and moderate inflammation (30%) were less. In the placebo group, 
44% of subjects with mild inflammation improved, compared to 18% improvement in those 
without inflammation and 22% of those with moderate inflammation. The presence of 
inflammation was not significantly associated with histologic improvement. Of those with 
any inflammation noted at baseline (n=53), 38% showed an improvement in Max, while 
only 22% of those without inflammation (n=22) had an improvement in Max (p=0.17).
Ki-67 analysis:
Biopsies from former smokers with baseline dysplasia (score of > 4) had Ki-67 staining 
completed to determine the proliferative index. A total of 42 pre- and post-treatment biopsy 
pairs from 19 subjects were evaluated and within this group there were biopsies that 
exhibited an improved histologic score (n=24), maintained the same score (n=13), and 
exhibited progression (n=5). A subject-level analysis (n = 19) of the association between 
baseline Ki-67 staining and change in mean histology score showed that baseline Ki-67 was 
not predictive of change in histology (p = 0.90). The pioglitazone treatment group exhibited 
a decrease in the Ki-67 proliferative index, with biopsies from subjects treated with 
pioglitazone exhibiting an average decrease in Ki-67 of 12%, as compared to placebo 
subjects who had an average increase of 3% for an overall treatment effect of −15% (p = 
0.077).
Adverse Events:
Study subjects were evaluated before the initial bronchoscopy and then had monthly clinic 
visits to evaluate for treatment related adverse events. Dropout rates were similar in the two 
treatment groups. The most common adverse events were: hypophosphatemia; hypertension; 
weight gain and hypocalcemia (Table 2S). There were no statistically significant differences 
in adverse events between the treatment groups except for hyperglycemia (12 events in 
placebo subjects compared to 4 events in the treatment group, p=0.028). These side effects, 
including lower rates of hyperglycemia in subjects on pioglitazone, are consistent with 
previously published trials of pioglitazone(22). Of note, no adverse cardiovascular events or 
bone fractures were noted during the trial in the group receiving pioglitazone. One subject 
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developed hematuria during the trial and was evaluated for bladder cancer (a known risk of 
cumulative TZD exposure in type 2 diabetics(23)), but a cancer diagnosis was not 
established. There was a single grade 5 adverse event (death due to alcohol abuse) from a 
subject treated with pioglitazone. There were no life-threatening adverse events (grade 4) in 
either group, and 20 severe (grade 3) adverse events; 13 in the placebo group and 7 in the 
pioglitazone group; 11 of the events were hypertension and 4 events were hypophosphatemia 
(the remaining five SAEs were each a single occurrence). No significant differences were 
observed between the two treatment groups for grade 3 adverse events (Table 2S contains 
the most common adverse events by treatment group).
Discussion
In this randomized, double-blind, placebo-controlled trial of pioglitazone we found that 6 
months of treatment did not significantly improve the pre-specified primary histologic 
endpoint of Max histology in former or current smokers. While there were individual lesions 
that improved (and persisted/progressed), there were no significant differences in the 
treatment groups of current or former smokers.
Endobronchial histology can be assessed using a variety of measures, including Max, Avg, 
and DI, none of which improved during this trial. While prior trials have chosen Avg as the 
primary endpoint, we chose to focus on Max as the more advanced lesions may be more 
likely to reflect invasive cancer risk. The natural history of dysplastic endobronchial lesions 
is difficult to predict. We published our experience where subjects with multiple 
bronchoscopic biopsies from the same area were evaluated over time. Subjects with multiple 
endobronchial dysplasias that persisted or progressed (based on repeat biopsies) had a 7.8 
fold higher rate of developing squamous cell lung cancer compared to those with 
improvement in histologic scores(7). Multiple trials, including the oral iloprost trial, have 
helped to better define the natural history of endobronchial dysplasia and demonstrate that 
merely obtaining an endobronchial biopsy does not produce a significant therapeutic effect. 
Most importantly, this report shows that dysplastic lesions can be targets of 
chemoprevention trials and, because they typically contain fewer genetic derangements and 
signaling abnormalities, they may also be amenable to treatment aimed at blocking 
progression.
Our recruitment model for this trial continues to show that we can successfully identify 
subjects with endobronchial dysplasia based on smoking history and sputum cytologic 
atypia. Of the 92 enrolled subjects, 64% (59/92) had at least one dysplastic (mild or worse) 
biopsy at baseline, and 48% (242/508) of the site-matched biopsy pairs scored at baseline 
were from histologically non-normal areas. These dysplasia rates compare favorably to our 
oral iloprost trial where 74% of the study subjects had at least one mildly dysplastic or 
worse biopsy, and 54% of the matched sites were from histologically non-normal areas(10). 
Ki-67 was selectively studied in former smokers who had dysplasia at baseline, and 
pioglitazone exhibited a trend (p=0.077) in decreasing Ki-67 by an average of 12%.
Identifying reliable and validated intermediate endpoint biomarkers for Phase II lung cancer 
chemoprevention trials has proven difficult. Sustained smoking cessation is the only known 
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intervention to impact lung cancer death rates(24). In the absence of proven effective agents, 
intermediate endpoints (endobronchial dysplasia and Ki-67 index) cannot be validated by 
the Prentice criteria(25), but they are a reasonable approach to assessment for further study 
in Phase III trials(6). Recently completed Phase II studies have chosen to evaluate the effects 
of intervention on pre-malignant lesions to further inform larger phase III trials. Phase II 
studies are now incorporating corollary studies that illustrate the chemopreventive agent has 
reached the desired target with a biological affect. For example, myoinositol inhibits 
phosphatidylinositol-3-kinase (PI3K), and some subjects receiving this intervention have 
gene expression signatures from endobronchial brushings that reflect PI3K inactivation(26). 
In our study, significantly lower rates of hyperglycemia were noted in the pioglitazone arm 
thereby confirming a known treatment effect.
For lung cancer chemoprevention to decrease incidence and improve survival, high risk 
populations must be identifiable. There are many published lung cancer risk models based 
on age, gender, smoking history, airflow obstruction, family history and radiographic 
emphysema which can risk stratify current or former smokers(27–29). The presence of 
COPD (as evidenced by airflow obstruction on spirometry or CT detected emphysema) also 
significantly increases lung cancer incidence(30,31). Our group previously reported that a 
cohort of high risk current and ex-smokers with airflow obstruction exhibited an overall rate 
of incident lung cancer of 1.85 per 100 person-years on longitudinal follow-up(21). 
Survivors of a previous tobacco associated aerodigestive cancer are an additional high risk 
population appropriate for phase II or III chemoprevention trials, and prior reports estimate 
second primary tumor rates in patients with a history of lung cancer at 1–2% per patient per 
year(4). Second primary lung cancer most commonly develops within 5 years of the initial 
diagnosis and equally in both genders(32). Advances in lesion characterization and biologic 
behavior will ultimately assist in identifying the highest risk lesions and should allow for 
more targeted treatment. Molecular or immunohistochemical analysis may improve the 
identification of lesions that will progress or which are associated with invasive lung cancer 
as a manifestation of a field effect(33–35). A recent study by our group comparing persistent 
to regressive bronchial dysplasia found altered cell-cycle control, inflammatory and 
adhesion related pathways(36). Of interest, biopsy inflammation was associated with 
regression, and this supports the results reported by Merrick et al. in their analysis of 
regressive lesions. For example, an improved understanding of the lesion immune 
microenvironment may allow for prevention with immune checkpoint inhibitors. Our group 
has initiated an immunoprevention trial evaluating a checkpoint inhibitor in high risk current 
and former smokers ().
Previous phase III chemoprevention trials were undertaken with agents without prior 
positive results in Phase II trials, and some of these agents had not demonstrated strong 
chemopreventive efficacy in animal models(37,38). Pioglitazone has shown efficacy in pre-
clinical models and the results of our trial prove that this agent cannot be used in subjects 
meeting our entry criteria. Based on clinical experience in treating lung cancer, it is 
understandable that a single agent may not prevent SCC. A better understanding of dysplasia 
biology will ultimately allow for the targeted treatment of the highest risk lesions, and an 
improved understanding of lesion characteristics that predict response to specific agents is 
needed. This may include, but is not limited to, the following characteristics: dysplasia 
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grade, persistence of dysplasia on multiple biopsies over time; Ki-67 index; gene expression 
signatures; and possibly inflammatory characteristics in the lesional microenvironment. 
Additionally, in this trial we report on a new biopsy parameter, the inflammation score. 
Success of immune oncology agents in the treatment of NSCLC suggest that the immune 
microenvironment plays a key role in lesion progression and cancer development. Our group 
is currently working to characterize the lesional microenvironment to determine if 
inflammatory characterization (as suggested by the trend toward an improved histologic 
response in lesions with baseline inflammation) is associated with response.
The current study, similar to many more recent phase II trials, was not powered to provide 
information about the clinically important endpoint of lung cancer incidence, and no study 
subjects developed lung cancer during the trial. All biopsy specimens were reviewed by a 
single pathologist. Dropout rates were similar between treatment groups, although the 
placebo group did have increased episodes of hyperglycemia. No cardiovascular events 
occurred in the pioglitazone treatment group during the study.
While smoking cessation will have the greatest impact on lung cancer reduction, effective 
chemoprevention could have major clinical application in the large population of former 
smokers. Additionally, the widespread adoption of CT screening in high risk population 
should increase the rates of stage I disease and lead to a larger group of survivors that remain 
at high risk for a second lung cancer. Identifying the highest risk lesions and studies of 
precision chemoprevention are warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: 
Trial Flow diagram.
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Figure 2: Primary Treatment Effects of Pioglitazone on Endobronchial Histology (Max, Average, 
Dysplasia Index) in All Subjects, Former Smokers, and Current Smokers
Comparison of Max histology measures on initial and follow-up bronchoscopy of subjects 
completing the trial (47 pioglitazone subjects, 45 placebo subjects). Biopsies were analyzed 
in the following groups: baseline (BL) non-normal; matched pairs; reference sites; and all 
sites. No significant differences are observed in former or current smokers.
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Figure 3: Inflammation results.
All biopsies received an inflammation score (0–3) at baseline and after 6 months of 
pioglitazone or placebo. Biopsies were analyzed in the following groups: baseline (BL) non-
normal; matched pairs; reference sites; and all sites.
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Table 1:
Baseline Characteristics of Trial Subjects
Comparison of Baseline Study characteristics (including the presence of inflammation) of subjects on 
pioglitazone or placebo. The only significant difference observed was older age in the placebo group.
Characteristic Pioglitazone (N=47) Placebo (N=45) Total (N=92) P-Value
Sex
 Male N (%) 39 (83.0) 38 (84.4) 77 (83.7) 0.85
 Female 8 (17.0) 7 (15.6) 15 (16.3)
Ethnicity
 Hispanic N (%) 4 (8.5) 2 (4.4) 6 (6.5) 0.43
 Non-Hispanic 43 (91.5) 43 (95.6) 86 (93.5)
Race
 White N (%) 44 (93.6) 38 (84.4) 82 (89.1) 0.30
 Black 2 (4.3) 6 (13.3) 8 (8.7)
 American Indian 1 (2.1) 1 (2.2) 2 (2.2)
Age at Enrollment (Years) Mean (SD) 58.6 (9.6) 62.6 (8.2) 60.5 (9.1) 0.036
Smoking Status
 Current Smoker N (%) 22 (46.8) 22 (48.9) 44 (47.8) 0.84
 Former Smoker 25 (53.2) 23 (51.1) 48 (52.2)
Age Stopped Smoking Mean (SD) 49.9 (11.6) 49.4 (13.1) 49.7 (12.2) 0.87
Packs per Day Mean (SD) 1.2 (0.5) 1.2 (0.4) 1.2 (0.5) 0.59
Smoking Duration (Years) Mean (SD) 34.9 (11.2) 35.9 (13.3) 35.4 (12.2) 0.72
Smoke Exposure (Pack-Years) Mean (SD) 41.7 (19.8) 41.0 (19.4) 41.4 (19.5) 0.87
Sputum Classification
 No Sputum Abnormalities N (%) 4 (8.5) 2 (4.4) 6 (6.5) 0.70
 Mild Sputum Atypia 26 (55.3) 25 (55.6) 51 (55.4)
 Moderate Sputum Atypia 10 (21.3) 13 (28.9) 23 (25.0)
 Severe Sputum Atypia 6 (12.8) 4 (8.9) 10 (10.9)
 Unknown 1 (2.1) 1 (2.2) 2 (2.2)
FEV1 (BL) Mean (SD) 2.74 (0.82) 2.68 (0.91) 2.71 (0.86) 0.74
FEV1 Predicted (BL) Mean (SD) 3.45 (0.59) 3.22 (0.66) 3.34 (0.63) 0.086
FEV1 % Predicted (BL) Mean (SD) 79.8 (20.2) 82.7 (21.1) 81.2 (20.5) 0.50
FVC (BL) Mean (SD) 3.78 (0.72) 3.73 (0.99) 3.76 (0.86) 0.80
FEV1/FVC Ratio Mean (SD) 0.71 (0.13) 0.71 (0.12) 0.71 (0.13) 0.88
COPD
 No N (%) 37 (78.7) 33 (73.3) 70 (76.1) 0.54
 Yes 10 (21.3) 12 (26.7) 22 (23.9)
Had Any Inflammation 0.58
 No N (%) 15 (31.9) 12 (26.7) 27 (29.3)
 Yes 32 (68.1) 33 (73.3) 65 (70.7)
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